Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The purpose of this open-label, non-comparative, multi-center protocol was to further evaluate safety and to provide treatment with ICL670 to patients who had or were at risk of life threatening complications due to transfusional iron overload with a documented inability to tolerate any of the commercially available iron chelators due to severe toxicity rendering continued therapy either impossible or hazardous. Patients who were also ineligible for all on-going registration trials with ICL670 were included in the study. In exceptional cases, patients with a degree of iron overload which was not immediately life-threatening and who were ineligible for the registration trials were also enrolled provided they had a well-documented, sound justification for alternative chelation therapy.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Patients with transfusional iron overload who were not experiencing severe toxicities during therapy with other iron chelators (e.g. deferoxamine and/or deferiprone).
Patients with non-transfusional hemosiderosis.
Patients with severe liver failure as defined by a score of ≥ 10 points on the Child-Pugh scale.
Patients with serum creatinine 1.5 times the upper limit of normal (ULN) at screening.
Patients with a history of nephrotic syndrome.
Patients with a diagnosis of clinically relevant cataract or a previous history of clinically relevant ocular toxicity related to iron chelation therapy.
Patients with severe systemic diseases unrelated to iron overload and which would prevent them from undergoing treatment with ICL670.
Patients with psychiatric or addictive disorders which prevent them from giving informed consent or undergoing treatment with ICL670.
Pregnant or breast feeding patients.
Patients treated with systemic investigational drugs within the past four weeks or topical investigational drugs within the past seven days.
Any surgical or medical condition which might significantly alter the absorption or excretion of drugs as shown by evidence of any of the following:
Patients being considered by the investigator as potentially unreliable and/or not cooperative with regard to the protocol.
History of drug or alcohol abuse within the 12 months prior to dosing.
Primary purpose
Allocation
Interventional model
Masking
30 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal